ABOUT THE RESEARCHER

OVERVIEW

Dr. Alal Eran is a computational biologist studying the molecular basis of autism.  She is fascinated by the clinical and molecular complexity of neurodevelopmental disorders, and enthusiastic about the possibilities of deciphering their underlying gene-environment interactions by integrating large datasets of functional genomic measurements and clinical information.

Dr. Eran has been studying RNA-mediated regulation at the synapse of children with autism as compared to neurotypical individuals, using deep sequencing of RNA and DNA.  She is interested in understanding the diagnostic and prognostic values of A-to-I RNA editing levels, striving to enable earlier diagnosis and more personalized care for children with autism.

 

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Melanocytes determine angiogenesis gene expression across human tissues. PLoS One. 2021; 16(5):e0251121. View abstract
  2. The National Autism Database of Israel: a Resource for Studying Autism Risk Factors, Biomarkers, Outcome Measures, and Treatment Efficacy. J Mol Neurosci. 2020 09; 70(9):1303-1312. View abstract
  3. A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia. Nat Med. 2020 09; 26(9):1375-1379. View abstract
  4. Racial disparity in Covid-19 mortality rates - A plausible explanation. Clin Immunol. 2020 08; 217:108481. View abstract
  5. Efficient Genomic Interval Queries Using Augmented Range Trees. Sci Rep. 2019 03 25; 9(1):5059. View abstract
  6. Association of Sex With Recurrence of Autism Spectrum Disorder Among Siblings. JAMA Pediatr. 2017 11 01; 171(11):1107-1112. View abstract
  7. Combining clinical and genomics queries using i2b2 - Three methods. PLoS One. 2017; 12(4):e0172187. View abstract
  8. A model-driven methodology for exploring complex disease comorbidities applied to autism spectrum disorder and inflammatory bowel disease. J Biomed Inform. 2016 10; 63:366-378. View abstract
  9. Jagged 1 Rescues the Duchenne Muscular Dystrophy Phenotype. Cell. 2015 Nov 19; 163(5):1204-1213. View abstract
  10. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum Mol Genet. 2015 Aug 01; 24(15):4480-1. View abstract
  11. Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. Hum Mol Genet. 2014 Apr 01; 23(7):1869-78. View abstract
  12. Can we measure autism? Sci Transl Med. 2013 Oct 30; 5(209):209ed18. View abstract
  13. Haplotype structure enables prioritization of common markers and candidate genes in autism spectrum disorder. Transl Psychiatry. 2013 May 28; 3:e262. View abstract
  14. Characteristics and predictive value of blood transcriptome signature in males with autism spectrum disorders. PLoS One. 2012; 7(12):e49475. View abstract
  15. Comparative RNA editing in autistic and neurotypical cerebella. Mol Psychiatry. 2013 Sep; 18(9):1041-8. View abstract
  16. Characterization of recovery and neuropsychological consequences of orbitofrontal lesion: A case study. Neurocase. 2011 Jun; 17(3):285-93. View abstract
  17. Comment on "Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients". J Clin Invest. 2009 Apr; 119(4):679-80; author reply 680-1. View abstract
  18. Distinctive patterns of microRNA expression in primary muscular disorders. Proc Natl Acad Sci U S A. 2007 Oct 23; 104(43):17016-21. View abstract